HIGHLIGHTS
- who: Srishti Chakravorty from the Shimane University, Japan have published the research: EBV-associated diseases: Current therapeutics and emerging technologies, in the Journal: (JOURNAL)
- what: One of the main reasons for EBV reactivation during transplantation is the use of immunosuppressants to prevent transplant rejection.
- future: Studies are needed to identify specific inhibitors of other latent EBV proteins including LMP1 or viral genes that are essential for EBV transformation. A further studies are needed to identify novel compounds and/or overcome these limitations. Studies are needed to determine its translation to the clinical setting . . .
If you want to have access to all the content you need to log in!
Thanks :)
If you don't have an account, you can create one here.